Management of Asthma: The Potential Role of Zafirlukast
Abstract
Asthma is a chronic inflammatory disorder of the airways. The worldwide prevalence of asthma has increased in recent decades. There is an approximately 20-fold variation (range 1.6% to 36.8%) in the prevalence of childhood asthma throughout the world. The highest prevalence rates are in the UK, Australia, New Zealand, the Republic of Ireland and Canada. The indirect costs of asthma, which include absence from school, lost productivity and premature death, are substantial. The goals of asthma therapy include controlling the disease and maintaining the well-being of the patient. Identification and avoidance of factors that precipitate asthma attacks are important in achieving satisfactory control of asthma. A stepped-care approach to drug therapy, in which anti-inflammatory therapy is the cornerstone, is recommended. Zafirlukast is a cysteinyl leukotriene type 1 receptor antagonist that causes bronchodilation and has anti-inflammatory properties. Oral zafirlukast 20mg twice daily was more effective than placebo in relieving symptoms, improving lung function, reducing requirements for as-needed beta2-agonists and preventing exacerbations in patients >=12 years of age with mild to moderate asthma. Zafirlukast 20mg twice daily produced improvements in symptoms and reductions in as-needed beta2-agonist rescue medication similar to inhaled sodium cromoglycate in patients with asthma. As an alternative to inhaled corticosteroids, zafirlukast 20mg twice daily produced improvements in night-time wakenings, mornings with asthma and reductions in the use of beta2-agonist rescue medication in patients with mild to moderate asthma. However, beclomethasone dipropionate 200 to 250microg twice daily produced greater improvement than zafirlukast in all efficacy parameters and significantly greater improvements in morning peak expiratory flow rate, forced expiratory volume in 1 second and daytime symptoms than zafirlukast. In patients with asthma uncontrolled on low dosages of inhaled corticosteroids, the addition of oral zafirlukast 40 or 80mg twice daily was as effective as doubling the dose of the inhaled corticosteroid. The most common adverse events associated with zafirlukast in trials <=20 weeks long were pharyngitis, headache and aggravation reactions, the incidence of which was similar to that in placebo recipients. Drug-drug interactions involving zafirlukast and aspirin, erythromycin, terfenadine, theophylline and warfarin have been described. Zafirlukast is indicated for the prophylactic treatment of chronic asthma. The drug is currently recognised in the US guidelines as an alternative to inhaled corticosteroids in patients aged >=12 years with mild persistent asthma. As an adjunct to corticosteroids, the role of zafirlukast is still evolving, but it seems likely that patients with asthma of all severities may benefit from the drug.Download Info
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic Info
Article provided by Wolters Kluwer Health | Adis in its journal Disease Management & Health Outcomes.
Volume (Year): 4 (1998)
Issue (Month): 6 ()
Pages: 337-353
Download reference. The following formats are available: HTML
(with abstract),
plain text
(with abstract),
BibTeX,
RIS (EndNote, RefMan, ProCite),
ReDIF
Handle: RePEc:wkh:dmhout:v:4:y:1998:i:6:p:337-353
Contact details of provider:
Web page: http://diseasemanagement.adisonline.com/
For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).
Related research
Keywords: Reviews-on-disease; Reviews-on-treatment; Asthma; Cost-of-illness; Zafirlukast; Corticosteroids; Zafirlukast; Drug-interactions; Quality-of-life; Cost-analysis; Patient-preference;Find related papers by JEL classification:
- C - Mathematical and Quantitative Methods
- D - Microeconomics
- I - Health, Education, and Welfare
- Z - Other Special Topics
- I1 - Health, Education, and Welfare - - Health
- I19 - Health, Education, and Welfare - - Health - - - Other
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
References
No references listed on IDEASYou can help add them by filling out this form.
Citations
Lists
This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.Statistics
Access and download statisticsCorrections
When requesting a correction, please mention this item's handle: RePEc:wkh:dmhout:v:4:y:1998:i:6:p:337-353For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.